Laise, P., Bosker, G., Babor, M., Sun, X., Andrews, S., Tomassoni, L., Califano, A., & Alvarez, M. (2025). Systematic identification and targeting of master regulator checkpoints (MRC) governing tumor microenvironment-mediated immune evasion. Journal for ImmunoTherapy of Cancer, 13(6), e011355. https://doi.org/10.1136/jitc-2024-011355

Borot, F., Humbert, O., Ehmsen, J. T., Fields, E., Kohli, S., Radtke, S., Swing, K., Pande, D., Enstrom, M. R., Laszlo, G. S., Mayuranathan, T., Ali, A. M., Weiss, M. J., Yen, J. S., Newby, G. A., Walter, R. B., Liu, D. R., Mukherjee, S., & Kiem, H.-P. (2025). Multiplex base editing to protect from CD33 directed drugs for immune and gene therapy. Nature Communications, 16(1). https://doi.org/10.1038/s41467-025-59713-2

Morris, Z. S., Demaria, S., Monjazeb, A. M., Formenti, S. C., Weichselbaum, R. R., Welsh, J., Enderling, H., Schoenfeld, J. D., Brody, J. D., McGee, H. M., Mondini, M., Kent, M. S., Young, K. H., Galluzzi, L., Karam, S. D., Theelen, W. S. M. E., Chang, J. Y., Huynh, M. A., Daib, A., … Fong, L. (2025). Proceedings of the National Cancer Institute Workshop on combining immunotherapy with radiotherapy: challenges and opportunities for clinical translation. The Lancet Oncology, 26(3), e152–e170. https://doi.org/10.1016/s1470-2045(24)00656-9

Yoon, A. J., Carvajal, R. D., Graboyes, E. M., Kaczmar, J. M., Albergotti, W. G., Kejner, A. E., Troob, S. H., Philipone, E., Anoma, J.-S., Armeson, K. E., Hill, E. G., Richardson, M. S., Woods, T. R., Chera, B. S., Nourollah-Zadeh, F., Lee, B. J., Pandruvada, S., Kourtidis, A., Kingsley, C., … Newman, J. G. (2025). Pilot clinical trial of neoadjuvant toll-like receptor 7 agonist (Imiquimod) immunotherapy in early-stage oral squamous cell carcinoma. Frontiers in Immunology, 16. https://doi.org/10.3389/fimmu.2025.1530262

Redenti, A., Im, J., Redenti, B., Li, F., Rouanne, M., Sheng, Z., Sun, W., Gurbatri, C. R., Huang, S., Komaranchath, M., Jang, Y., Hahn, J., Ballister, E. R., Vincent, R. L., Vardoshivilli, A., Danino, T., & Arpaia, N. (2024). Probiotic neoantigen delivery vectors for precision cancer immunotherapy. Nature, 635(8038), 453–461. https://doi.org/10.1038/s41586-024-08033-4

Gao, L., & Ding, L. (2024). METTL3: Melting the tumor microenvironment for improved immunotherapy. Cell Chemical Biology, 31(4), 629–631. https://doi.org/10.1016/j.chembiol.2024.03.005

Goubet, A.-G., Rouanne, M., Derosa, L., Kroemer, G., & Zitvogel, L. (2023). From mucosal infection to successful cancer immunotherapy. Nature Reviews Urology, 20(11), 682–700. https://doi.org/10.1038/s41585-023-00784-5

Miholjcic, T. B. S., Halse, H., Bonvalet, M., Bigorgne, A., Rouanne, M., Dercle, L., Shankar, V., & Marabelle, A. (2023). Rationale for LDH-targeted cancer immunotherapy. European Journal of Cancer, 181, 166–178. https://doi.org/10.1016/j.ejca.2022.11.032

Obradovic, A. (2023). Precision immunotherapy. Science, 379(6633), 654–655. https://doi.org/10.1126/science.adg5585

Klein, R. M. (2022). Calvin Coolidge’s “rose fever.” Annals of Allergy, Asthma & Immunology, 129(1), 125–126. https://doi.org/10.1016/j.anai.2022.03.034

de Vries, E. G., & Schwartz, L. H. (2022). Perspectives on imaging and immunotherapy: a review series. Journal for ImmunoTherapy of Cancer, 10(6), e005006. https://doi.org/10.1136/jitc-2022-005006

Schöffski, P., Tan, D. S. W., Martín, M., Ochoa-de-Olza, M., Sarantopoulos, J., Carvajal, R. D., Kyi, C., Esaki, T., Prawira, A., Akerley, W., De Braud, F., Hui, R., Zhang, T., Soo, R. A., Maur, M., Weickhardt, A., Krauss, J., Deschler-Baier, B., Lau, A., … Hong, D. S. (2022). Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies. Journal for ImmunoTherapy of Cancer, 10(2), e003776. https://doi.org/10.1136/jitc-2021-003776

Lombardo, K. A., Obradovic, A., Singh, A. K., Liu, J. L., Joice, G., Kates, M., Bishai, W., McConkey, D., Chaux, A., Eich, M., Rezaei, M. K., Netto, G. J., Drake, C. G., Tran, P., Matoso, A., & Bivalacqua, T. J. (2021). BCG invokes superior STING‐mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer. The Journal of Pathology, 256(2), 223–234. Portico. https://doi.org/10.1002/path.5830

Leighl, N. B., Redman, M. W., Rizvi, N., Hirsch, F. R., Mack, P. C., Schwartz, L. H., Wade, J. L., Irvin, W. J., Reddy, S. C., Crawford, J., Bradley, J. D., Stinchcombe, T. E., Ramalingam, S. S., Miao, J., Minichiello, K., Herbst, R. S., Papadimitrakopoulou, V. A., Kelly, K., & Gandara, D. R. (2021). Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). Journal for ImmunoTherapy of Cancer, 9(8), e002973. https://doi.org/10.1136/jitc-2021-002973

Ager, C. R., Boda, A., Rajapakshe, K., Lea, S. T., Di Francesco, M. E., Jayaprakash, P., Slay, R. B., Morrow, B., Prasad, R., Dean, M. A., Duffy, C. R., Coarfa, C., Jones, P., & Curran, M. A. (2021). High potency STING agonists engage unique myeloid pathways to reverse pancreatic cancer immune privilege. Journal for ImmunoTherapy of Cancer, 9(8), e003246. https://doi.org/10.1136/jitc-2021-003246